NeuBase Therapeutics, Inc.
NBSE · NASDAQ
9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $0 | $0 |
| Gross Profit | -$1 | -$1 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $21 | $14 | $7 | $17 |
| G&A Expenses | $12 | $12 | $10 | $9 |
| SG&A Expenses | $12 | $12 | $10 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $33 | $27 | $17 | $26 |
| Operating Income | -$33 | -$27 | -$17 | -$26 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | $1 | -$0 | -$1 |
| Pre-Tax Income | -$34 | -$25 | -$17 | -$27 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$34 | -$26 | -$17 | -$27 |
| % Margin | – | – | – | – |
| EPS | -21.08 | -18.8 | -17.6 | -65.49 |
| % Growth | -12.1% | -6.8% | 73.1% | – |
| EPS Diluted | -21.08 | -18.8 | -17.6 | -65.49 |
| Weighted Avg Shares Out | 2 | 1 | 1 | 0 |
| Weighted Avg Shares Out Dil | 2 | 1 | 1 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$33 | -$26 | -$17 | -$27 |
| % Margin | – | – | – | – |